N@N

CELG, CBPO, CBM, BPAX, BNVI, AVII, Biomed - Genetics Stocks 6.07% undervalued

^{Published on 2011-01-26 12:42:46 - WOPRAI}
 

January 26, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring the Biomed - Genetics sector and these stocks are the most undervalued as of today. CELGENE CORP (NASDAQ:CELG), CHINA BIOLOGIC PRODUCTS INC (NASDAQ:CBPO), CAMBREX CORP (NYSE:CBM), BIOSANTE PHARMACEUTICALS INC (NASDAQ:BPAX), BIONOVO INC (NASDAQ:BNVI), AVI BIOPHARMA INC (NASDAQ:AVII) are all expected to go Up as they are undervalued according to industry standard valuation metrics. The valuation model employs a three-factor approach to stock valuation using fundamental variables--the company's trailing 12-month Earnings-Per-Share (EPS), the analyst consensus estimate of the company's forecasted 12-month EPS, and the 30-year Treasury yield--to create a highly accurate reflection of a company's fair value.

The chart below displays the projected Fair Value and Valuation discount/premium of the most undervalued stocks in the highlighted industry group:

     Symbol     Company Name                        Last Close     Fair Value     Valuation                   Industry               
     CELG       CELGENE CORP                        56.07          59.69          6.07% undervalued           Biomed - Genetics      
     CBPO       CHINA BIOLOGIC PRODUCTS INC         15.87          16.27          2.47% undervalued           Biomed - Genetics      
     CBM        CAMBREX CORP                        4.96           7.42           33.14% undervalued          Biomed - Genetics      
     BPAX       BIOSANTE PHARMACEUTICALS INC        1.97           2.32           15.19% undervalued          Biomed - Genetics      
     BNVI       BIONOVO INC                         1.15           2.94           60.92% undervalued          Biomed - Genetics      
     AVII       AVI BIOPHARMA INC                   2.21           2.26           2.30% undervalued           Biomed - Genetics      

Here are some of the variables that are utilized when calculating the Fair Market Valuation of a stock: Long-run EPS growth rate, Duration of Business-growth-cycle, Volatility of EPS growth rate, Systematic or beta risk of the firm, Correlation between the firm's EPS and the interest rate environment, EPS growth volatility, Dividend payout ratio, Buffer earnings, Interest rate related criteria: Interest rate (30 year yield) long-run level, Duration of interest rate cycle, Interest rate volatility. The Fair Market Valuation uses 12-month historic and forecasted EPS values and the current 30-year treasury yield as primary determinants. When calculating risk/return values such as the Sharpe ratio, the historic periods used are five years.

Some expected results of the Valuation Model are: the valuation of a stock increases in a declining interest rate environment. Increasing current and/or projected EPS will produce a higher Valuation. While long-term EPS growth would produce a corresponding long-term Valuation increase, concomitant long-term interest rate increases would offset EPS growth and depress the Valuation. The shorter a company's own business cycle, the higher its stock Valuation will be.

CELGENE CORP (NASDAQ:CELG) - Celgene Corporation discovers, develops, and commercializes innovative therapies to treat cancer and immune-inflammatory diseases in the United States, Europe, and internationally. Its commercial stage products include REVLIMID for the treatment in combination with dexamethasone for multiple myeloma patients, as well as patients with transfusion-dependent anemia; and THALOMID to treat, in combination with dexamethasone, patients with newly diagnosed multiple myeloma, as well as for the prevention and suppression of cutaneous manifestations of erythema nodosum leprosum recurrence. The company also sells VIDAZA, used to subtypes of myelodysplastic syndromes; RITALIN to treat attention deficit hyperactivity disorder; FOCALIN to prevent oncology-related disorders; and ALKERAN to treat multiple myeloma and carcinoma of the ovary. Its development stage products consist of CC-4047, which is in Phase I and Phase II clinical trials for treating disease indications, including sickle cell anemia, myelofibrosis, and multiple myeloma; CC-10004, a Phase II clinical trial product for psoriasis and psoriatic arthritis; CC-11050, a Phase I clinical trial completed product for inflammatory conditions; CC-401, a Phase I clinical trial completed product to identify kinases that regulate pathways critical in inflammation and oncology; CC-930, a Phase Ib clinicial trial completed product for fibrotic conditions; and Amrubicin, a Phase III clinical trial product for small cell lung cancer treatment. In addition, the company is researching stem cells derived from the human placenta, as well as from the umbilical cord. Celgene Corporation has strategic collaborations with Acceleron Pharma, Inc. and Agios Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.

CHINA BIOLOGIC PRODUCTS INC (NASDAQ:CBPO) - China Biologic Products, Inc., a biopharmaceutical company, engages in the research, development, production, and manufacture of plasma-based pharmaceutical products in the People's Republic of China. It offers Human Albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; prevention and cure of low-density-lipoproteinemia; and Neonatal hyperbilirubinemia. The company also provides Human Hepatitis B Immunoglobulin for the prevention of measles and contagious hepatitis; Human Immunoglobulin and Human Immunoglobulin for Intravenous Injection for original immunoglobulin deficiency, secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides Injection as a cure for various original and secondary T-cell deficiency syndromes, auto-immune deficiency diseases, and various cell immunity deficiency diseases, as well as assists in the treatment for tumors. In addition, it offers Human Rabies Immunoglobulin for passive immunity from bites or claws by rabies, or other infected animals; and Human Tetanus Immunoglobulin for the prevention and therapy of tetanus. The company s products under development include Human Prothrombin Complex Concentrate, Human Coagulation Factor VIII, Human Hepatitis B Immunoglobulin (PH4) for intravenous injection, Human Fibrinogen, Varicella Hyperimmune Globulins, and Human Immunoglobulin for intravenous injection. It sells its products primarily to hospitals and inoculation centers through distributors. The company was founded in 1971 and is based in Taian City, the People's Republic of China.

CAMBREX CORP (NYSE:CBM) - Cambrex Corporation, a life sciences company, provides products and services for the development and commercialization of new and generic therapeutics. Its products include active pharmaceutical ingredients and pharmaceutical intermediates for use in the production of prescription and over-the-counter drug products, and other custom chemicals derived from organic chemistry. The company sells its products through sales agents and independent agents to pharmaceutical and generic drug companies worldwide. Cambrex Corporation was founded in 1981 and is based in East Rutherford, New Jersey.

BIOSANTE PHARMACEUTICALS INC (NASDAQ:BPAX) - BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company, develops products for female sexual health, menopause, contraception, and male hypogonadism. The company offers Elestrin, a transdermal estradiol (estrogen) gel, which is marketed in the United States for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. It also develops LibiGel, a transdermal testosterone gel that is in Phase III development for the treatment of female sexual dysfunction; Pill-Plus, which is a combination of estrogens, progestogens, and androgens for the treatment of female sexual dysfunction in women using oral or transdermal contraceptives; and Bio-T-Gel, a transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency in men. In addition, the company develops calcium phosphate technology (CaP) for aesthetic medicine, as a vaccine adjuvant, and for drug delivery. Its CaP products in development comprise BioLook, which is a facial line filler in development using proprietary CaP technology in the area of aesthetic medicine; BioVant, a CaP adjuvant and delivery technology for vaccines against viral and bacterial infections and autoimmune diseases; BioOral, a delivery system for oral/buccal/intranasal administration of proteins and other therapies; and BioAir, a delivery system for inhalable versions of proteins and other therapies. The company was founded in 1996 and is based in Lincolnshire, Illinois.

BIONOVO INC (NASDAQ:BNVI) - Bionovo, Inc., a clinical stage drug discovery and development company, focuses on womens health and cancer primarily in the United States. Its lead drug candidate, Menerba, which completed a Phase II clinical trial, is a receptor sub-type selective estrogen receptor modulator for the treatment of vasomotor symptoms of menopause. Bionovo also develops Bezielle, an oral anti-cancer agent for advanced breast cancer, which completed two Phase I clinical trials; and Seala, a Phase I/II trial candidate for the treatment of post-menopausal vulvar and vaginal atrophy. It also develops BN107 and BN108, which are anticancer agents. The company was founded in 2002 and is headquartered in Emeryville, California.

AVI BIOPHARMA INC (NASDAQ:AVII) - AVI BioPharma, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products based on antisense and cancer immunotherapy technology. The companys products under development comprise AVI-4658, which has completed Phase I human clinical trials to restore, prevent, or slow deterioration of muscle function; and AVI-5038, a preclinical stage product that is designed to skip exon 50, and overcome the mutational block and restore dystrophin expression. Its other development programs include AVI-6002 Ebola virus program, AVI-6003 Marburg virus program, and AVI-7367 H1N1 virus program. It has strategic alliances with Chiron Corporation; Cook Group Incorporated; Ercole Biotech, Inc.; Eleos Inc.; Charleys Fund, Inc.; and the United States Department of Defense. The company was founded in 1980 and is headquartered in Bothell, Washington.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net